ArticleMolecular therapy. Oncology2025
Near-infrared photoimmunotherapy for effective elimination of ovarian cancer cells by inducing immunogenic cell death.
Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer represents one of the most common forms of female gynecological cancer. The existing treatment modalities include surgery and chemotherapy, which are unable to treat local and long-distant micro-metastases. Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed treatment strategy that can selectively kill the cancer cells and induce immunogenic cell death and thereby stimulate anti-tumor immune responses. In this study, we developed five NIR-PIT agents by conjugating scFv-SNAP-tag fusion proteins with BG-modified IRdye700 to target ovarian cancer cells, which expressed cell surface antigens epidermal growth factor receptor (EGFR), Her2, FOLR1, TROP2, and TF. Flow cytometry and microscopic studies confirmed the specificity of all the investigated NIR-PIT agents binding to corresponding overexpressed cancer cells. In addition, all the investigated NIR-PIT agents demonstrate specific binding to human ovarian cancer tissues, as confirmed by multiplex immunofluorescence imaging. We validated that all five NIR-PIT agents decreased the cell viability in a concentration-dependent manner with IC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.